< Back to Site

References

  1. Stites EC, Shaw AS. Quantitative systems pharmacology analysis of KRAS G12C covalent inhibitors. CPT Pharmacometrics Syst Pharmacol. 2018;7(5):342-351. doi:10.1002/psp4.12291.
  2. Shukla S, Allam US, Ahsan A, et al. KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation. Neoplasia. 2014;16(2):115-128. doi:10.1593/neo.14184.
  3. Bergo MO, Gavino BJ, Hong C, et al. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest. 2004;113(4):539-550. doi:10.1172/JCI18829.
  4. Svaton M, Fiala O, Pesek M, et al. The prognostic role of KRAS mutation in patients with advanced NSCLC treated with second- or third-line chemotherapy. Anticancer Res. 2016;36(3):1077-1082.
  5. Liu SY, Sun H, Zhou JY, et al. Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients. Biomark Res. 2020;8(22). doi: 10.1186/s40364-020-00199-z.
  6. Nadal E, Beer DG, Ramnath N. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. J Thorac Oncol. 2015;10(2):e9-e10. doi:10.1097/JTO.0000000000000438.
  7. Bonnot PE, Passot G. RAS mutation: site of disease and recurrence pattern in colorectal cancer. Chin Clin Oncol. 2019;8(5):55. doi:10.21037/cco.2019.08.11.
  8. Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011;17(5):1122-1130. doi:10.1158/1078-0432.CCR-10-1720.
  9. Yaeger R, Cowell E, Chou JF, et al. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer. 2015;121(8):1195-1203. doi:10.1002/cncr.29196.
  10. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014;13(11):828-851. doi:10.1038/nrd4389.
  11. Haigis KM. KRAS alleles: The devil is in the detail. Trends Cancer. 2017;3(10):686-697. doi:10.1016/j.trecan.2017.08.006.
  12. Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: Striking a moving target. JCI Insight. 2018;3(15):e120858. https://doi.org/10.1172/jci.insight.120858.
  13. Hobbs GA, Der CJ, Rossman KL. Ras isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129:1287-1292. doi:10.1242/jcs.182873.
  14. Yang H, Liang S, Schmid RA, Peng R. New horizons in KRAS-mutant lung cancer: Dawn after darkness. Front Oncol. 2019;9(953):1-13. doi: 10.3389/fonc.2019.00953.
  15. Fernández-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011;2(3):344-358. doi:10.1177/1947601911411084.
  16. Waters AM, Der CJ. KRAS: The critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med. 2018;8(9):a031435. doi:10.1101/cshperspect.a031435.
  17. McCormick F. K-Ras protein as a drug target. J Mol Med (Berl). 2016;94(3):253-258. doi:10.1007/s00109-016-1382-7.
  18. Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170(1):17-33. doi:10.1016/j.cell.2017.06.009.
  19. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013(503):548–551. doi:10.1038/nature12796.
  20. Patricelli MP, Janes MR, Li LS, et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 2016;6(3):316-329. doi:10.1158/2159-8290.CD-15-1105.
  21. Lito P, Solomon M, Li LS, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016;351(6273):604-608. doi:10.1126/science.aad6204.

Share